BlackRock
ENTA icon

BlackRock’s Enanta Pharmaceuticals ENTA Stock Holding History

BlackRock’s Portfolio ENTA Stock Details ENTA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$39.2M Buy
3,103,768
+27,486
+0.9% +$368K ﹤0.01% 2676
2025
Q4 		$48.5M Buy
3,076,282
+1,243,302
+68% +$15.8M ﹤0.01% 2533
2025
Q3 		$21.9M Sell
1,832,980
-13,925
-0.8% -$111K ﹤0.01% 3041
2025
Q2 		$14M Sell
1,846,905
-171,764
-9% -$1.03M ﹤0.01% 3228
2025
Q1 		$11.1M Sell
2,018,669
-20,973
-1% -$130K ﹤0.01% 3264
2024
Q4 		$11.7M Buy
2,039,642
+139,319
+7% +$1.34M ﹤0.01% 3346
2024
Q3 		$19.7M Buy
1,900,323
+52,804
+3% +$690K ﹤0.01% 3056
2024
Q2 		$24M Buy
1,847,519
+8,464
+0.5% +$114K ﹤0.01% 2866
2024
Q1 		$32.1M Sell
1,839,055
-95,656
-5% -$1.27M ﹤0.01% 2714
2023
Q4 		$18.2M Sell
1,934,711
-44,349
-2% -$413K ﹤0.01% 3062
2023
Q3 		$22.1M Sell
1,979,060
-1,751,638
-47% -$28.2M ﹤0.01% 2889
2023
Q2 		$79.8M Sell
3,730,698
-45,704
-1% -$1.35M ﹤0.01% 2197
2023
Q1 		$153M Buy
3,776,402
+22,278
+0.6% +$1.06M ﹤0.01% 1742
2022
Q4 		$175M Buy
3,754,124
+132,329
+4% +$6.03M 0.01% 1637
2022
Q3 		$188M Buy
3,621,795
+103,059
+3% +$6.02M 0.01% 1518
2022
Q2 		$166M Buy
3,518,736
+2,130
+0.1% +$116K 0.01% 1659
2022
Q1 		$250M Buy
3,516,606
+45,191
+1% +$2.94M 0.01% 1503
2021
Q4 		$260M Sell
3,471,415
-123,638
-3% -$9.7M 0.01% 1542
2021
Q3 		$204M Sell
3,595,053
-76,953
-2% -$3.8M 0.01% 1704
2021
Q2 		$162M Sell
3,672,006
-57,565
-2% -$2.82M ﹤0.01% 1937
2021
Q1 		$184M Buy
3,729,571
+323,571
+10% +$16.1M 0.01% 1790
2020
Q4 		$143M Buy
3,406,000
+190,493
+6% +$8.38M ﹤0.01% 1845
2020
Q3 		$147M Buy
3,215,507
+185,216
+6% +$8.97M 0.01% 1636
2020
Q2 		$152M Buy
3,030,291
+198,393
+7% +$10.3M 0.01% 1555
2020
Q1 		$146M Buy
2,831,898
+8,330
+0.3% +$444K 0.01% 1386
2019
Q4 		$174M Buy
2,823,568
+211,377
+8% +$13.1M 0.01% 1603
2019
Q3 		$157M Buy
2,612,191
+19,834
+0.8% +$1.47M 0.01% 1590
2019
Q2 		$219M Buy
2,592,357
+37,417
+1% +$3.37M 0.01% 1366
2019
Q1 		$244M Sell
2,554,940
-18,548
-0.7% -$1.66M 0.01% 1259
2018
Q4 		$182M Sell
2,573,488
-16,678
-0.6% -$1.28M 0.01% 1388
2018
Q3 		$221M Buy
2,590,166
+157,166
+6% +$15.7M 0.01% 1414
2018
Q2 		$282M Buy
2,433,000
+68,564
+3% +$6.84M 0.01% 1172
2018
Q1 		$191M Buy
2,364,436
+20,843
+0.9% +$1.6M 0.01% 1398
2017
Q4 		$138M Buy
2,343,593
+97,054
+4% +$4.86M 0.01% 1645
2017
Q3 		$105M Buy
2,246,539
+48,342
+2% +$1.94M 0.01% 1831
2017
Q2 		$79.1M Sell
2,198,197
-96,690
-4% -$3.09M ﹤0.01% 1958
2017
Q1 		$70.7M Buy
2,294,887
+2,286,323
+26,697% +$71.2M ﹤0.01% 2012
2016
Q4 		$287K Buy
8,564
+293
+4% +$8.4K ﹤0.01% 1931
2016
Q3 		$220K Buy
8,271
+3,657
+79% +$84.9K ﹤0.01% 2098
2016
Q2 		$102K Buy
4,614
+3,448
+296% +$90.3K ﹤0.01% 2526
2016
Q1 		$34K Buy
1,166
+809
+227% +$22.5K ﹤0.01% 2568
2015
Q4 		$12K Hold
357
– – ﹤0.01% 2802
2015
Q3 		$13K Hold
357
– – ﹤0.01% 2604
2015
Q2 		$16K Buy
357
+123
+53% +$4.79K ﹤0.01% 2503
2015
Q1 		$7K Hold
234
– – ﹤0.01% 2906
2014
Q4 		$12K Hold
234
– – ﹤0.01% 2646
2014
Q3 		$9K Hold
234
– – ﹤0.01% 2780
2014
Q2 		$10K Buy
+234
New +$8.93K ﹤0.01% 2768

Other funds holding ENTA

Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
KAM
Krensavage Asset Management New York $256M AUM 69.63% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
SSC
Spruce Street Capital New York $416M AUM
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

BlackRock's ENTA Position: Q1 2026 in Review

BlackRock increased its Enanta Pharmaceuticals (ENTA) stake by 0.89% in Q1 2026, buying an estimated $368K and bringing the position to 3,103,768 shares worth $39.2M. The position accounts for ﹤0.01% of the portfolio, ranked #2676.

BlackRock first reported a position in ENTA in Q2 2014 and has held it in 48 quarters since. The position peaked at $282M in Q2 2018. 132 funds tracked by Wall St. Rank hold ENTA as of Q1 2026.

  • BlackRock held 3,103,768 shares of Enanta Pharmaceuticals worth $39.2M as of Q1 2026.
  • BlackRock bought 27,486 Enanta Pharmaceuticals shares in Q1 2026, an estimated $368K.
  • Enanta Pharmaceuticals made up ﹤0.01% of BlackRock's portfolio in Q1 2026, its #2676 holding.
  • BlackRock first reported a position in Enanta Pharmaceuticals in Q2 2014 and has held it in 48 quarters since.
  • BlackRock's Enanta Pharmaceuticals position peaked at $282M in Q2 2018.
  • 132 funds tracked by Wall St. Rank held Enanta Pharmaceuticals as of Q1 2026.

Based on BlackRock's 13F filing for Q1 2026, filed 13 May 2026.